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Evidence of the risk of birth defects with efavirenz
use is limited. We updated a meta-analysis of birth
defects in infants with first trimester efavirenz
exposure up to July 2011. In 21 studies, there were
39 defects among live births in 1437 women receiv-
ing first trimester efavirenz [2.0%, 95% confidence
interval (CI) 0.82–3.18]. The relative risk of defects
comparing women on efavirenz-based (1290 live
births) and nonefavirenz-based regimens (8122 live
births) was 0.85 (95% CI 0.61–1.20). One neural
tube defect was observed (myelomeningocele),
giving an incidence of 0.07% (95% CI 0.002–0.39).
Current antiretroviral treatment guidelines in resource-
limited settings recommend efavirenz or nevirapine as
first-line drugs [1]. Efavirenz is widely used because it is
well tolerated, easy to monitor, conveniently coformu-
lated as a once-daily pill and shows similar virologic
suppression to nevirapine. However, efavirenz use during
the first trimester of pregnancy is contraindicated due to
animal data and case reports indicating a potential
association with neural tube defects [2]. We previously
published a systematic review and meta-analysis that
found no increase in overall birth defects comparing first
trimester receipt of efavirenz-based and nonefavirenz-
based regimens, although the limited number of reports
prevented a definitive conclusion regarding the risk of
rare outcomes such as neural tube defects [3]. We updated
our systematic review to include data up to July 2011.
Using a predefined protocol (http://tinyurl.com/
3hzz5wo), we combined terms for efavirenz, pregnancy
and birth outcomes and searched the following databases
up to 1 July 2011 without language restrictions:
MEDLINE via PubMed; EMBASE; CINAHL and
PsycInfo; Cochrane CENTRAL; LILACS; Current Con-
trolled Trials; BioMedCentral and Public Library of Science;
and websites of major HIV conferences such as
International AIDS Society conferences up to July
2011 and Conferences on Retroviruses and Opportu-
nistic Infections up to February 2011. Data were
abstracted from the latest Antiretroviral Pregnancy
Registry (http://www.apregistry.com), and the following
treatment cohorts were contacted: the MTCT Plus
Initiative; Me´decins Sans Frontie`res; the InternationalCopyright © Lippincott Williams & Wilkins. Unau
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ISSN 0269-9370 Q 2011 Wolters Kluwer HeaEpidemiologic Databases to Evaluate AIDS in Southern
Africa (IeDA-SA); and the Reproductive Health
Research Unit (RHRU).
The primary endpoint was birth defects of any kind.
Unsystematic observations (case series or case reports)
were excluded. Point estimates and 95% confidence
intervals (CIs) were calculated for birth defects reported
among live births for each study (spontaneous and
induced abortions and stillbirths were excluded).
Proportions were summarized using random effects
meta-analysis using a Freeman–Tukey arcsine transform-
ation of the raw proportions. The t2-statistic was
calculated to assess between-study heterogeneity. For
cohorts reporting birth outcomes of infants exposed to
efavirenz vs. other antiretrovirals during the first
trimester, relative risks (RRs) and CIs were calculated
and data pooled using random effects method. Subgroup
analyses assessed potential effects on the pooled estimates
of study design, location, exposure duration and
publication status. All analyses were conducted using
Stata, version 11 (StataCorp LP, College Station, Texas,
USA).
The initial search yielded 798 publications and 885
conference abstracts, from which 32 studies were
reviewed as full text. Twenty-one studies were included
for analysis (among which 19 reported our primary
outcome), including 13 prospective studies. This updated
review found 181 additional live births with first trimester
efavirenz exposure and birth defect data from five
additional cohorts [4–8], one updated study [9] of a
previous report [10], and the updated Antiretroviral
Pregnancy Registry [11].
Across the 19 studies reporting birth defects among 1437
live-born infants born to women receiving efavirenz in
the first trimester, birth defect prevalence ranged from 0%
[12] to 22.6% [13], with a 2.0% pooled prevalence (CI
0.82–3.18); heterogeneity between studies was low
(t2¼ 1.89). One neural tube defect was observed
(myelomeningocele) [11], giving an incidence pro-
portion of 0.07% (CI 0.002–0.39) (Table 1) [4–9,
11–23]. In a subgroup analysis, there was no difference
according to publication status (P¼ 0.58), study design
(P¼ 0.19) or exposure duration (P¼ 0.96); prevalence
appeared higher in developed countries compared with
developing countries (P¼ 0.015).
Eleven studies reported birth defects among infants born to
women receiving first trimester efavirenz-containing
regimens (38 defects among 1290 live births) andthorized reproduction of this article is prohibited.
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Table 1. Description of reported birth defects in infants born to women with first trimester efavirenz exposure.
Study
Number of with
EFV exposure in
first trimester
Mean duration of
EFV exposure during
pregnancy
Number of
pregnancies
with live births
Number of
birth defects
(live births) Description of birth defects
Antiretroviral Pregnancy
Registry, [11]
623 623 17a Myelomeningocele (n¼1),
anophthalmia with severe
oblique facial clefts and
amniotic band on arm
Ekouevi et al. [9] 203 59 days 147 0 NR
Phanuphak et al. [4] 7 NS 6 0 NR
Cressey et al. [5] 4 NS 4 0 NR
Westreich et al. [14] 60 NS 60 0 NR
Blood et al. [7] 2 NS 1b 0 NS
Areechokchai [6] 5 NS 5 0 NR
Bera et al. [15] 195 39 weeks 184 5c Arthrogryposis multiplex
congenitald, oesophageal
atresia with trachea
oesophageal fistula,
polysyndactylye, postaxial
polydactyly, central lower
incisor
Townsend et al. [16] 205 NS 204 5 undescended testes (n¼2),
hip dislocation (n¼2),
hypertrophic pyloric
stenosis
Machado et al. [17] 19 Not reported 18 1 Undescended testes
Gonzalez-Tome et al. [13] 31 2 months 31 7 Renal dilatation (n¼4),
angiomatosis, dermoid
cyst, acetabular dysplasia,
inguinal hernia
Oliveira [8] 17 NS 17 0 NR
Rossouw et al. [18] 37 NS 31 0 NR
Bussmann et al. [19] 38 43 days 22 1 Bone dysplasia
Floridia et al. [20] 39 NS 32 2 Bilateral clubfoot,
undescended testes
Joao et al. [12] 23 15 weeks (median) 21 0 NR
Jeantils et al. [21] 12 8 weeks 7 1f Right arm angioma
Patel et al. [22] 19 40 days 19 0 NR
Batallan et al. [23] 5 23.7 weeks 5 0 NR
EFV, efavirenz; NS, not specified; NR, not reported.
aDetailed information on type of birth defects in the Antiretroviral Pregnancy Registry only provided for the two central nervous system defects.
bOne woman defaulted.
cOne additional birth defect was noted in stillbirth (trisomy 18).
dArthrogryposis multiplex congenita: birth defects included joint contractures, webbed limbs, pulmonary hypoplasia, absent sacrum and unilateral
cleft lip and palate.
ePolysyndactyly, polysyndactyly with syndactyly: extra digits fully formed with phanges and nail, fingers were postaxial and toes were pre-axial
fused with big toe.
fOne additional birth defect was noted on autopsy of medically aborted fetus (multiple malformations including pulmonary segmentation, bicuspid
pulmonary value and accelerated skeletal maturation without genetic abnormalities).nonefavirenz-containing regimens (316 defects among
8122 live births), giving a nonsignificant RR of 0.85 (CI
0.61–1.20); heterogeneity was low (t2¼ 0) (Fig. 1). The
pooled estimate was not affected by subgroup analyses that
compared study setting (P¼ 0.47), duration of efavirenz
exposure (P¼ 0.78) or publication status (P¼ 0.50).
The reporting of secondary outcomes varied across
studies. Eight studies reported spontaneous abortions,
with prevalence raging from 0% [6] to 16.05% [14]. The
prevalence of stillbirths, reported by eight studies, ranged
from 0% [19] to 13.3% (MTCT-Plus). The prevalence for
termination of pregnancy, reported by 10 studies ranged
from 0% [6] to 33.7% [24]. Three studies reported data on
termination of pregnancy (none based on prenatal
screening) for women exposed to efavirenz-containingpyright © Lippincott Williams & Wilkins. Unauthoand nonefavirenz-containing regimens [9,19,24], giving a
RR of 2.81 (95% CI 0.94–8.36) for efavirenz-exposed
women. Finally, five studies reported on preterm delivery,
with prevalence ranging from 9.1% [19] to 18.2% [20].
The methodological quality of included studies was
judged to be moderate. The vast majority of reports were
from prospective cohorts (1364 live births), and only four
studies were composed of less than 10 patients with first
trimester efavirenz use. Ascertainment of birth defects
among stillborn/terminated births was only reported by
two studies (the prevalence of birth defects was consistent
with data reported for live births).
This expanded review confirms the previous meta-
analysis findings of no increased risk of overall birthrized reproduction of this article is prohibited.
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Year
2010
2010
2010
2010
2010
2010
2011
2011
2010
2011
2011
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13
16
15
22
20
17
9
4
19
11
5
0.85 (0.61, 1.20)
risk (95% CI)
0.65 (0.33, 1.26)
0.75 (0.30, 1.87)
0.90 (0.11, 7.43)
1.33 (0.08, 21.51)
1.22 (0.28, 5.31)
6.22 (0.41, 95.10)
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0.75 (0.07, 7.78)
0.92 (0.56, 1.50)
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38/1290
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0/4
316/8122
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1/33
14/770
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0/102
0/180
2/33
147/4932
0/21
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Fig. 1. Relative risk of birth defects on efavirenz vs. nonefavirenz regimens. CI, confidence interval; EFV, efavirenz.defects among women receiving first trimester efavirenz.
The pooled prevalence of birth defects for women
exposed to first trimester efavirenz (2.0%) is similar to that
for women exposed to nonefavirenz-based regimens in
the antiretroviral pregnancy registry (2.9%) [11], and in
the general population (6%) [25]. Incidence of neural
tube defects remains low (0.07%), but this estimate is
derived from a small sample.
Strengths of this review include a broad search strategy
that identified data from the grey literature and
unpublished cohorts, and the inclusion of updated data
for several cohorts. Limitations include the inconsistent
reporting of secondary outcomes and the potential for
bias associated with selective abortion as a result of
prenatal screening that could result in a reduction of birth
prevalence. We consider such bias unlikely, given that
none of the studies reporting rates of termination of
pregnancy among women exposed to efavirenz used
prenatal screening to guide termination decisions and
note that in the Antiretroviral Pregnancy Registry the
reported prevalence of birth defects among induced
abortuses of women exposed to antiretroviral therapy in
the first-trimester (2.5%) is consistent with the back-
ground prevalence [11]. The main limitation of this
review is the small sample size. It is notable that more than
80% of data come from just four studies in which
prospective reporting of birth outcomes has beenCopyright © Lippincott Williams & Wilkins. Unautestablished [9,11,15,16]. The lack of systematic recording
of birth outcomes from women receiving antiretroviral
drugs during pregnancy persists, with reports of birth
outcome data for only 181 live births found by this review
in the last 18 months. Prospective surveillance systems
particularly in developing countries are needed to
improve data reporting and inform the assessment of
risk of rare defects.Acknowledgements
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